US Edition
CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting
- On June 1, 2025, CARsgen Therapeutics announced positive Phase II trial results of satricabtagene autoleucel in advanced gastric/gastroesophageal junction cancer in Shanghai.
- The CT041-ST-01 trial evaluated satri-cel in patients with Claudin18.2-positive tumors who had not responded to two or more previous treatment regimens, addressing a critical gap in therapy for solid tumors.
- The randomized controlled trial showed improved progression-free survival, overall survival, and tumor response rates, marking a milestone in CAR-T therapy for solid tumors.
- Satri-Cel has obtained Orphan Drug and Regenerative Medicine Advanced Therapy classifications from the U.S. FDA, and in China, it has been recognized by the NMPA's Center for Drug Evaluation with special regulatory status that expedites its review process for treating advanced Claudin18.2-positive gastric/gastroesophageal junction adenocarcinoma.
- CARsgen intends to file an application with China's NMPA this month seeking approval for satri-cel as the first commercial CAR-T therapy targeting solid tumors, which could provide new treatment options for patients with limited alternatives.
65 Articles
65 Articles
Bennington Banner
CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting
SHANGHAI, June 1, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the results of the pivotal Phase II clinical trial in China (CT041-ST-01, NCT04581473) investigating satricabtagene autoleucel…
CARsgen showcases Satri-cel breakthroughs at ASCO 2025 and in The Lancet
SHANGHAI, June 2, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the results of the pivotal Phase II clinical trial in China (CT041-ST-01, NCT04581473) investigating satricabtagene autoleucel ("satri-cel", CT041) (a Claudin18.2-specific autologous CAR T-cell product candidate) in patients with Claudin18.2-positive, advanced gastric/…
Coverage Details
Bias Distribution
- 63% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
